Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 16, 2021updated 07 Jan 2022 8:43am

ZOLL Medical completes acquisition of Itamar Medical

Itamar Medical will now operate as a business division within ZOLL.

ZOLL Medical has completed its previously announced acquisition of medical device and digital health company Itamar Medical.

The acquisition closed nearly three months after ZOLL signed a definitive agreement to acquire Itamar Medical for nearly $538m.

As agreed, Itamar Medical will now operate as a business division within ZOLL. The former CEO of Itamar Medical, Gilad Glick, will lead the business.

The acquired firm’s main operations in Caesarea, Israel, are also expected to continue with no material impact.

Itamar Medical focuses on developing non-invasive medical devices and solutions to help diagnose respiratory sleep disorders. The company’s main product, the WatchPAT Home Sleep Apnea Device, is available in the US, Europe and Japan.

The acquisition will enable ZOLL to enhance its offerings for undiagnosed and untreated cardiac patients.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

ZOLL CEO Jon Rennert said: “We are pleased to announce the closing of the acquisition of Itamar and welcome its employees to the ZOLL family.

“Together, ZOLL and Itamar Medical will help more patients receive diagnosis and treatment for sleep-disordered breathing and help strengthen the collaboration between the worlds of cardiology and sleep medicine.”

An Asahi Kasei subsidiary, ZOLL delivers medical devices and software solutions for emergency care as well as to boost clinical and operational efficiencies.

Last year, ZOLL secured US Food and Drug Administration (FDA) approval for its TherOx System.

The TherOx System is designed to provide SuperSaturated Oxygen (SSO₂) Therapy and reduce heart muscle damage in ‘widowmaker’ heart attack patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy